Many TNBC Patients Unnecessarily Opt for Mastectomy
The use of neoadjuvant chemotherapy increases eligibility for breast-conserving therapy in triple-negative breast cancer patients, yet many still opt for mastectomy.
Neoadjuvant Chemotherapy Improves Clinical Response in Breast Cancer
For premenopausal breast cancer patients, 24 weeks of neoadjuvant chemotherapy may yield a better clinical response than endocrine therapy.
Olaparib Improves Outcomes in BRCA-Mutated Metastatic Breast Cancer
The PARP inhibitor olaparib increases progression-free survival and improves quality of life in BRCA-mutated HER2-negative metastatic breast cancer patients.
2 Commerce Drive Cranbury, NJ 08512